Articles tagged with: Patients

AR alterations and therapy resistance in prostate cancer

Posted in General News, Publications Published by Bethan Warman 16 May 2019

AR alterations and therapy resistance in prostate cancer

Recent findings from a study published in JAMA Oncology have identified genetic markers within blood samples which may indicate whether patients with prostate cancer will respond to hormonal therapies. The study may represent an important step forward for the development of more personalised treatments for advanced prostate cancer.

IBD and bowel cancer: Predicting patient risk

Posted in General News, Interviews Published by Bethan Warman 30 April 2019

Bowel Cancer Awareness Month

IBD and bowel cancer: Predicting patient risk

April is Bowel Cancer Awareness Month. We recently spoke with Dr Kit Curtius about her work which focuses on understanding how normal tissues evolve to become cancerous, with a particular interest in gastrointestinal pre-malignancies such as inflammatory bowel disease (IBD).

Phase I clinical trial finds combination therapy to be well-tolerated in patients with high-grade gliomas

Posted in General News, Publications Published by Bethan Warman 29 March 2019

Phase I clinical trial finds combination therapy to be well-tolerated in patients with high-grade gliomas

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients. The trial used a treatment combination of ADI-PEG20, pemetrexed and cisplatin, which showed encouraging efficacy in patients with recurrent high-grade gliomas (HGGs), a disease for which little progress has been made over the last few decades.

Resistance in Ovarian Cancer

Posted in General News Published by Bethan Warman 13 March 2019

Ovarian Cancer Awareness Month

Resistance in Ovarian Cancer

This month is Ovarian Cancer Awareness Month. In the UK each year, around 7,300 women are diagnosed with ovarian cancer, making it the sixth most common cancer type in females. Here at the Barts Cancer Institute, our researchers are working to better understand the biology of ovarian cancer and translate this knowledge into new diagnostic and treatment strategies. One particular focus of our ovarian cancer research is understanding and combating the development of resistance to therapy, which is a major obstacle in the successful treatment of many cancer types.

Dr Manchanda becomes NHS Innovation Accelerator Fellow for Population-based Genetic Testing

Posted in General News, Grants & Awards Published by Bethan Warman 05 March 2019

Dr Manchanda becomes NHS Innovation Accelerator Fellow for Population-based Genetic Testing

Dr Ranjit Manchanda was announced today as one of 13 Fellows to join the NHS Innovation Accelerator (NIA), which supports dedicated individuals to scale their high impact, evidence-based innovations across the NHS and wider healthcare system.

Combination therapy improves survival in advanced kidney cancer

Posted in General News Published by Bethan Warman 13 February 2019

Combination therapy improves survival in advanced kidney cancer

A combination therapy has shown powerful anticancer responses in patients with a type of advanced kidney cancer in a new international phase III clinical trial (KEYNOTE-426). Treatment with the combination therapy resulted in significant increases in overall survival when compared with the current standard of care, and the findings will help to provide a vital new treatment option for patients with this disease.

Tackling tumour scar tissue could be key to treating pancreatic cancer

Posted in General News, Publications Published by Administrator 11 February 2019

Tackling tumour scar tissue could be key to treating pancreatic cancer

The first study in the world to take a detailed look at scar tissue in human pancreatic cancer has revealed a range of different scar tissue types that could help clinicians predict which patients will respond best to particular treatments.

Genomics project reaches goal of 100,000 genomes sequenced from NHS patients

Posted in General News Published by Administrator 06 December 2018

Genomics project reaches goal of 100,000 genomes sequenced from NHS patients

UK Health Secretary Matt Hancock announced yesterday that a project involving Queen Mary University of London researchers has reached its goal of sequencing 100,000 whole genomes from NHS patients. The 100,000 Genomes Project, led by Genomics England in partnership with NHS England, is a ground-breaking programme which has been based at Queen Mary’s Charterhouse Square campus since 2013, involving 24 of its staff members.

Tackling the deadliest cancer type

Posted in General News Published by Bethan Warman 30 November 2018

Our lung cancer research

Tackling the deadliest cancer type

This month is Lung Cancer Awareness Month. Lung cancer is the third most common cancer in the UK, with 46,700 new cases diagnosed each year. Approximately 35,600 people lose their lives annually as a result of lung cancer in the UK, making it the most common cause of cancer-related mortality. Only 5% of those affected survive their cancer for 10 years or more in the UK, and this survival rate has not shown much improvement over the last four decades.

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

Posted in General News, BCI on the Road, Publications Published by Bethan Warman 22 October 2018

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

New research led by Barts Cancer Institute and St Bartholomew’s Hospital has provided new hope for people with an aggressive type of breast cancer. The phase 3 clinical trial has shown that by using a combination of immunotherapy and chemotherapy, the body’s own immune system can be tuned to attack triple-negative breast cancer, extending survival by up to ten months.

[12 3  >>  
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.